Fri, Dec 19, 2014, 8:02 AM EST - U.S. Markets open in 1 hr 28 mins

Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics Inc. Message Board

  • mauihope1969 mauihope1969 Mar 20, 2014 1:22 PM Flag

    Case for opportunistic offering

     

    This seems the perfect time for what Clay has termed an "opportunistic offering" which he refused to rule out or signal when or if it will ever happen. They guided for $250ml cash at the end of 2014, down form the $374ml at the end of 2013. An 80ml cash burn. 10ml shares now at $50 would have them end 2014 with $750ml-$1bl cash.
    That would give them pockets deep enough to not only push the pipeline but perhaps expand some of the more promising collaboration deals to co-development deals. Companies like CLDX and PGNX will need partners to bring their drugs to market. The measly 3-5% royalty could be be instead 50-50.
    In the long run 10ml shares will make no difference when Adcetris achieves frontline. The 500ml cash now would add far more value.
    I'm in favor of such a move now while the stock price is range bound.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
SGEN
33.04+0.90(+2.80%)Dec 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.